IDSA Disclaimer As of the time of this publication, updates have been made to IDSA's
Guidelines on the Diagnosis of COVID-19. For the most updated version of these guidelines …

At the beginning of the COVID-19 pandemic, patients with immune-mediated inflammatory
diseases were considered to be at high risk for SARS-CoV-2 infection and the development …

Background The risk of severe acute respiratory syndrome‐related coronavirus 2 (SARS‐
CoV‐2) infection and clinical outcomes of coronavirus disease (COVID‐19) in inflammatory …

Background & Aims Vaccination against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has rapidly expanded; however, clinical trials excluded patients taking …

Background Our understanding of coronavirus disease 2019 (COVID-19) and its
implications for patients with inflammatory bowel diseases (IBD) is rapidly evolving. We …

Abstract Background and Aims As no population-based study has investigated the
susceptibility and disease course of COVID-19 among patients with inflammatory bowel …

Abstract Background and Aims The COVID-19 risk and disease course in inflammatory
bowel disease [IBD] patients remains uncertain. Therefore, we aimed to assess the clinical …

Background Accurate estimates for the risk of COVID‐19 in IBD, and an understanding of the
impact of COVID‐19 on IBD course and the risk of incident post‐infectious IBD are needed …

Background The effect of immunosuppressive treatment for immune-mediated diseases on
risk of the novel coronavirus disease 2019 (COVID-19) has not been established. We aimed …

Background & Aims Data on the clinical characteristics of patients with inflammatory bowel
diseases (IBDs) with coronavirus disease 2019 (COVID-19) are scarce. The aim of our …